Enter your contact details & our Business Development
expert will circle back to address your request!
In 2021, the market for Biological Skin Substitutes worldwide was worth $0.71 billion US dollars. AMR Group projects that the market will reach US$ 1.34 billion by 2031, growing at a CAGR of 5.2 percent between 2022 and 2031.
Biological Skin Substitutes are organic, synthetic, or metabolic processes materials that are utilized to cover a wide wound in order to rebuild at least some of the skin's capabilities. Skin substitutes focus on providing temporary or permanent tissue repair, as well as protection from infection, further damage, and moisture loss, as well as pain management. They also aid the normal skin to develop over the wound. Skin substitutes are used to treat a variety of conditions such as burns, trauma wounds, insulin resistance, and venous ulcers in which skin grafts really aren't possible.
The Biological Skin Substitutes market contains a variety of consumables and equipment that are required at various stages of the Biological Skin Substitutes technique in order to understand the basic biochemistry and biology of cells. It functions as a model system and can be used for a variety of purposes including cancer research, stem cell research, bio production, diagnostics, and drug screening. Factors driving the market include increased biopharmaceutical market growth, rising demand for monoclonal antibodies, rising prevalence of chronic diseases, increased research funding, and rising adoption of single-use technologies. Furthermore, recent advances in gene expression technologies have enabled the development of novel vaccines and biopharmaceuticals, expanding the research and development applications of Biological Skin Substitutes techniques.
The Biological Skin Substitutes market tends to grow due to the rising chronic skin diseases is anticipated to propel the market growth. According to the global burden of disease study, skin conditions contributed approximately 1.79% of the global disease burden in 2021. As reported by the World Health Organization, approximately 132,000 melanoma skin cancers are diagnosed worldwide each year. Thus, rising chronic diseases will increase the need for skin substitutes over the forthcoming years. Furthermore, the rising incidence of diabetes in the market is expected to propel the Biological Skin Substitutes market forward. This is due to the higher risk of foot ulcers from diabetes development in diabetic patients over period. Cell-based research studies aided in understanding the cells' reactions to any chemical and identifying novel modules that can be used to improve people's health.
Increasing public awareness of treatment options that have become available in recent years has also contributed to market growth in the forecast years. People want advanced and novel burn care products, and the introduction of new products will fuel market growth. Because of the growing need to maintain high-quality standards and adhere to regulatory bodies' guidelines, the cost of tissue biology research has risen significantly. As a result, they lack the ability to form differentiated structures such as hair and sweat glands. As a result, the need to include additional types of cells in engineered skin, such as endothelial cells, is a restraining factor in the global Biological Skin Substitutes market.
The COVID-19 pandemic has negatively impacted the Biological Skin Substitutes Markets major pharmaceutical and biotech companies. During the pandemic, they worked together to develop vaccines and treatment methods. The collaboration's goal was to form alliances and evaluate solutions as early as possible during the pandemic period, which would not be possible with any single organization alone. Joint ventures were also formed within universities and businesses to expedite the research and production processes. During the pandemic, pharmaceutical and biotechnological research was also outsourced to contract research organizations (CROs). Acelity and Scapa Healthcare have agreed to transition Systagenix's manufacturing facility in September 2020. This transaction will increase the focus on innovation, development, and commercialization of an expanded advanced wound dressing portfolio in order to compete in the market.
The global Biological Skin Substitutes market is divided into five regions: North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. Globally, due to an increase in burns and chronic skin diseases, North America dominates the market for Biological Skin Substitutes. Rising burn cases are expected to propel the market over the forecast period. According to the Global Burden of Disease Report, 8.378,122 new burn cases were discovered globally. In 2019, approximately 111,292 deaths were recorded. According to the American Burn Association, 128 burn centers admitted more than 60% of the estimated US acute hospitalizations for burns in 2019. Furthermore, the healthcare burden in the United States of America, which includes direct costs for the care of children with burns, exceeded US$ 211 million.
Due to increased demand for tissue engineered skin substitutes, a rapidly growing medical tourism industry, and an increase in medical approvals, as well as the presence of developing countries such as China, India, and Japan in the region, Asia Pacific is expected to register a higher. Furthermore, the tissue designed skin substitutes market offers detailed market analysis for each country, including growth in healthcare expenditure for capital equipment, installed base of various types of products for the tissue engineered skin substitutes market, impact of technology using life line curves, and modifications in healthcare regulatory scenarios and about their impact on the tissue engineered skin substitutes market.
Key players operating in the global Biological Skin Substitutes market are Abbott Laboratories, Amarantus Bioscience Holdings, Inc., Avery Therapeutics, Inc., Berkeley Advanced Biomaterials, Biomimetic Solutions, CAM Bioceramics B.V., ConvaTec Group PLC, CRS Holdings Inc., Essity Medical Solutions, GELITA AG, Integra LifeSciences, Kerecis, LifeNet Health, Mallinckrodt, Medline Industries, Inc., MiMedx, Mölnlycke Health Care AB, Olympus Corporation, Organogenesis Inc, Regenicin, Smith & Nephew, Solvay, Terumo Corporation, The Lubrizol Corporation, Tissue Regenix, Wright Medical Group N.V, and Zimmer Biomet among others. Recently, Organogenesis, a regenerative medicine company that develops and markets product solutions for advanced surgical and sports medicine, as well as wound care, announced in January 2021 that its product ReNu had been granted regenerative medicine advanced therapy designation by the US Food and Drug Administration. ReNu is a cryopreserved amniotic suspension allograft used to treat knee osteoarthritis symptoms.
The World Health Organization reported in January 2022 that the global incidence of diabetes for all age groups was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of diabetics is expected to rise from 171 million in 2000 to 366 million by 2030. As a result, the prevalence of diabetes-related skin problems is expected to rise during the forecast period.
Based upon the Type used in Biological Skin Substitutes market is segmented into three major segments Human Donor Tissue-derived Products, Acellular Animal-derived Products and Biosynthetic Products in the Biological Skin Substitutes process. Based on Application, the Biological Skin Substitutes market is segmented into Acute Wounds and Chronic Wounds. Among the application segments, the Acute Wounds segment is estimated to account for the largest share of the Biological Skin Substitutes market. The rapidly increasing number of surgeries performed and the rising numbers of burn injuries are the major factors contributing to this segment's large market share. According to the American Burn Association, burn injuries are one of the leading causes of accident or injury and death in the United States. The segment has been subdivided into surgery and trauma, as well as burn injuries.
End user segment of Biological Skin Substitutes market is further divided into Hospitals and Wound Care Centers. The Hospitals segment was accounted for the largest share of the Biological Skin Substitutes market. The rising number of surgeries is one of the factors driving this segment's large market share. Furthermore, the rising number of diabetic foot ulcers and venous leg ulcers are major driving factors for the segment.
• Human Donor Tissue-derived Products
• Acellular Animal-derived Products
• Biosynthetic Products
• Acute Wounds
o Surgery & Trauma
o Burn Injuries
• Chronic Wounds
o Diabetic Foot Ulcers
o Pressure Ulcers
o Venous Leg Ulcers
o Other Chronic Wounds
By End User
• Wound Care Centres
Please fill form below:
99 WALL STREET #2124 NEW YORK, NY 10005